Full Spectrum Hemp Observational Study

Status Not yet recruiting

Clinical Trial Summary

In westernized societies, acne vulgaris is nearly a universal skin disease afflicting 79% to 95% of the adolescent population; older than 25 years - 40% to 54% have facial blemishes and persists into middle age in 12% of women and 3% of men. Standard treatment modalities present with high risk morbidities. Charlotte's Web hemp blemish product is predicted to significantly reduce the risks mentioned above, while improving efficacy as well as imparting other skin benefits.

Clinical Trial Description

Charlotte's Web Full spectrum hemp blemish product will contain a mere 0.018% THC and will therefor not impart a psychotic affect. Hemp has been shown to be well tolerated in humans and has a very acceptable dosage, efficacy and safety profile when topically applied. The FDA has labeled hemp as Generally Regarded As Safe (GRAS) and as such reduces the risk of severe adverse reactions to the subject. Benefits of hemp blemish 'cream" is that it has been formulated in such a way as to promote natural skin balance, and may eliminate skin dryness, inflammation, hyperpigmentation, and scaring. The primary objective and endpoint of the study is to obtain total eradication of the blemish eruptions. The secondary objective and endpoints is the continued use of the hemp product will continue to prevent further blemish eruptions and provide other skin benefits especially reducing the propensity to scar. ;

Study Design

Related Conditions & MeSH terms

Acne Vulgaris
Acne Vulgaris Superficial Mixed Comedonal and Inflammatory

Clinical Trial Details

NCT number	NCT04730414
Study type	Observational [Patient Registry]
Source	Charlotte's Web, Inc
Contact	Sherry Bradford, PhD
Phone	7168607800
Email	sherry.bradford.ctr@charlottesweb.com
Status	Not yet recruiting
Phase
Start date	February 2021
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04321070` - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris	Phase 1
Recruiting	`NCT05755256` - The Impact of Probiotics on Skin Hydration in Youth With Mild Acne	Phase 2
Completed	`NCT05131373` - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris	Phase 1
Completed	`NCT01445301` - Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects	Phase 3
Completed	`NCT03303170` - Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris	N/A
Completed	`NCT04698239` - Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.	N/A
Completed	`NCT02886715` - A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris	Phase 3
Terminated	`NCT02924428` - Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris	N/A
Not yet recruiting	`NCT02491060` - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris	Phase 3
Not yet recruiting	`NCT02525822` - Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris	Phase 2
Completed	`NCT02709902` - Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris	Phase 1
Not yet recruiting	`NCT02535871` - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris	Phase 3
Completed	`NCT02250430` - A Phase 1 Study Assessing Local Cutaneous Effects of SB204	Phase 1
Completed	`NCT02913001` - The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne	N/A
Completed	`NCT01694810` - Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers	Phase 1
Completed	`NCT01769664` - A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris	Phase 1
Completed	`NCT01727440` - Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment	N/A
Completed	`NCT01194375` - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris	Phase 2
Completed	`NCT00991198` - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage	Phase 2
Completed	`NCT02524665` - 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne	Phase 4